Cell Cycle Perturbations of Platinum Derivatives on Two Ovarian Cancer Cell Lines

References

• Piver MS., Rose P G. Chemotherapy of epithelial ovarian cancer. Chemotherapy of Gynecologic Cancer, 2nd ed, G Deppe. Alan R Liss, New York 1990; 175–216
   Google Scholar
• Grew F, Hande A. KR., Jones H W. Advanced ovarian cancer: Long term follow-up after brief intensive chemotherapy. Proc Am Soc Clin Oncol 1984; 3: 166
   Google Scholar
• Thigpen J, Vance T. RB., Lainbuth B W. Ovarian carcinoma: The role of chemotherapy. Semin Oncol 1983; 15(3)16–23
   Google Scholar
• Wiltshaw E, Subramaranian S, Alexopoulos C. Cancer of the ovary: A summary of experience with cis-dichlorodi-ammineplatinum (II) at the Royal Marsden Hospital. Cancer Treat Rep 1979; 63: 1545–1548
   PubMedGoogle Scholar
• Ozols RF., Young R C. High-dose cisplatin therapy in ovarian cancer. Semin Oncol 1985; 12(4)21–30
   PubMed Web of Science ®Google Scholar
• Ozols R F, Ostchega Y, Myers C E. High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol 1985; 3: 1246–1250
   PubMed Web of Science ®Google Scholar
• Eichholtz-Wirth H, Hietel B. The relationship between cisplatin sensitivity and drug uptake into mammalian cells in vitro. Br J Cancer 1986; 54: 239–243
   PubMed Web of Science ®Google Scholar
• Kraker AJ., Moore C W. Accumulation of cis-diamminedichlo-roplatinum II and platinum analogues by platinum-resistant mu-rine leukemia cells in vitro. Cancer Res 1988; 48(1)9–13
   PubMedGoogle Scholar
• Richon V, Schulte M., Eastman N. A. Multiple mechanisms of resistance to cis-diamminedichloroplatinum (II) in murine leukemia L1210 cells. Cancer Res 1987; 47: 2056–2061
   PubMed Web of Science ®Google Scholar
• Waud W R, Blount S R. Biochemical studies on resistance to cis-platinum (cis-DDP) in L1210 leukemia. Proc Am Assoc Cancer Res 1985; 26: 260
   Web of Science ®Google Scholar
• Masuda H, Ozols R F, Lai G M. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichlo-roplatinum (II) in human ovarian cancer cell lines. Cancer Res 1988; 48: 5713–5716
   PubMed Web of Science ®Google Scholar
• Zwelling L A, Michaels S, Schwartz H. DNA cross-linkage an indicator of sensitivity and resistance of mouse L1210 leukemia to cis-diamminedichloroplatinum (II) and L-phenylalanine mustard. Cancer Res 1981; 41: 640–649
   PubMed Web of Science ®Google Scholar
• Andrews P A, Murphy M P, Howell S B. Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res 1985; 45(12)6250–6253
   PubMed Web of Science ®Google Scholar
• Hamilton T C, Winker M A, Louie K G. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and drug-sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol 1985; 34: 2583–2586
   PubMed Web of Science ®Google Scholar
• Smith E, Brock A P. An in vitro study comparing the cytotoxicity of three platinum complexes with regard to the effect of thiol depletion. Br J Cancer 1988; 57(6)548–552
   PubMed Web of Science ®Google Scholar
• Boike G, Petru M. E., Sevin B U. Chemical enhancement of cisplatin cytotoxicity in a human ovarian cancer cell line. Gynecol Oncol 1990; 38: 315–322
   PubMed Web of Science ®Google Scholar
• Canetta R, Rozencweig M., Carter S K. Carboplatin: The clinical spectrum to date. Cancer Treat Rev 1985; 12: 125–136
   PubMed Web of Science ®Google Scholar
• Wiltshaw E. Ovarian trials at the Royal Marsden. Cancer Treat Rev 1985; 12: 67–71
   PubMed Web of Science ®Google Scholar
• Anderson W K, Quagliato D A, Haugwitz R D. Synthesis, physical properties, and antitumor activity of tetraplatin and related tetrachloroplatinum (IV) stereoisomers of 1,2-diaminocy-clohexane. Cancer Treat Rep 1986; 70: 997
   PubMedGoogle Scholar
• Suzumori K, Yasui Y, Suzumori K. Comparative studies of the antitumor activities of CDDP and the analogs using gynecological carcinomas transplanted into nude mice. Can To Ka-gaku Ryoho 1989; 16(3)387–391
   PubMedGoogle Scholar
• Majima H. Present status of cisplatin (CDDP) analogues in Japan. Can To Kagaku Ryoho 1989; 16(4)1373–1378
   PubMedGoogle Scholar
• Fukuoka M, Niitani H, Hasegawa K. Phase I study of new platinum compound, NK121. Proc Am Soc Clin Oncol 1989; 8: 62
   Google Scholar
• Hills C A, Kelland L R, Abel G. Biological properties of ten human ovarian carcinoma cell lines: Calibration in vitro against four platinum complexes. Br J Cancer 1989; 59(4)527–534
   PubMed Web of Science ®Google Scholar
• Zwelling L A, Kohn K W. Mechanism of action of ris-dichloro-diammine-platinum (II). Cancer Treat Rep 1979; 63: 1439–1444
   PubMedGoogle Scholar
• Chabner B A, Myers C E. Clinical pharmacology of cancer chemotherapy. Cancer Principles and Practice of Oncology, Vol I, 3rd ed, VT Devita, S Hellman, SA Rosenberg. Lippincott, Philadelphia 1989; 373–375
   Google Scholar
• Sevin B, Ramos U. R, Averette H E. The potential use of cell kinetics in the treatment of ovarian malignancies. Cancer Campaign. Carcinoma of the Ovary, Vol 7, E Grund-mann. G Fisher Verlag, New York 1983; 23–38
   Google Scholar
• Sevin B U, Pollack A, Averette H E. In vivo chemosensitivity testing in patients with gynecologic malignancies and nude mouse xenografts by monitoring cell kinetic parameters and DNA distribution patterns: A preliminary report. Gynecol Oncol 1986; 24: 27–40
   PubMed Web of Science ®Google Scholar
• Sevin B U. DNA analysis and cell kinetics in gynecologic malignancies. Chemotherapy of Gynecologic Cancer, 2nd ed, G Deppe. Wiley, New York 1990; 443–461
   Google Scholar
• Geisinger K., Kute T., Pettenati M. Characterization of a human ovarian carcinoma cellline with estrogen and progesterone receptors. Cancer 1989; 63: 280–288
   PubMed Web of Science ®Google Scholar
• Buick R, Pullano R, Trent J. Comparative properties of five ovarian adenocarcinoma cell lines. Cancer Res 1985; 45: 3668–3676
   PubMed Web of Science ®Google Scholar
• Alberts D, Chen G. Tabular summary of pharmacokinetic parameters relevant to in vitro drug assay. Cloning of Human Tumor Stem Cells, S. Salmon. Alan R. Liss, New York 1980; 351–359
   Google Scholar
• Pollack A, Moulis H, Prudhomme D L. Flow cytometric analysis of cell kinetic responses using measurements of correlated DNA and nuclear protein. Clin Cytometry 1986; 46: 85–66
   Google Scholar
• Pollack A, Moulis H, Greenstein D B. Cell kinetic effects of incorporated 3H-thymidine on proliferating human lymphocytes: Flow cytometric analysis using the DNA/nuclear protein method. Cytometry 1985; 6: 428–436
   PubMedGoogle Scholar
• Kingston R E, Sevin B U, Ramos R. Synergistic effects of cisplatin and cytosine-arabinoside on ovarian carcinoma cell lines demonstrated by dual parameter flow cytometry. Gynecol Oncol 1988; 32: 282–287
   Web of Science ®Google Scholar
• Schiano M, Sevin A. B, Perras U. J. In vilro enhancement of cis-platinum antitumor activity by caffeine and pentoxifylline in a human ovarian cell line. Gynecol Oncol 1991; 43(1)37–45, 1991
   PubMed Web of Science ®Google Scholar
• Wolloch E, Sevin H. BU., Perras J. Cell kinetic perturbations after irradiation and caffeine in BG-I ovarian carcinoma cell line. Gynecol Oncol 1991; 43(1)26–36, 1991
   Google Scholar
• Petru E, Sevin B U, Perras I, Bnike Ramos C., Nguyen R. H., Averette H E. Comparative chemosensitivity profiles in four human ovarian carcinoma cell lines measuring ATP biolumines-cence. Gynecol Oncol 1990; 38: 155–160
   PubMed Web of Science ®Google Scholar